Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Research

• Publication date

  2009-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-08-2648PMID 19147566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure-function of the TNF receptor-like cysteine-rich domain of osteoprotegerin.

  2008influential reference
• Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.

  2007cited by this paper
• Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-κB ligand

  2007cited by this paper
• Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-kappa B ligand.

  2007influential reference
• Osteosarcoma (Osteogenic sarcoma)

  2007influential reference
• An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.

  2007influential reference
• INVESTIGATING THE INTERACTION BETWEEN OSTEOPROTEGERIN AND RANKL OR TRAIL: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS

  2007influential reference
• Proteoglycans: key partners in bone cell biology

  2007cited by this paper
• Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.

  2007influential reference
• Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies

  2007cited by this paper
• Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

  2007influential reference
• Role of osteoprotegerin (OPG) in cancer.

  2006influential reference
• RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.

  2006cited by this paper
• Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.

  2006influential reference
• Therapeutic value of glycosaminoglycans in cancer

  2006influential reference
• Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK

  2006cited by this paper
• Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

  2005influential reference
• Osteoprotegerin in prostate cancer bone metastasis.

  2005influential reference
• Amphiphilic Block Copolymers Promote Gene DeliveryIn Vivo to Pathological Skeletal Muscles

  2005cited by this paper
• Functional Dissection of Osteoprotegerin and Its Interaction with Receptor Activator of NF-κB Ligand*

  2005influential reference
• Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes.

  2005influential reference
• Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL‐Induced Apoptosis

  2004influential reference
• Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo*

  2004influential reference
• RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.

  2004cited by this paper
• Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis

  2004influential reference
• Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.

  2003influential reference
• A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

  2003influential reference
• Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

  2003influential reference
• Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.

  2003cited by this paper
• Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

  2002influential reference
• Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation.

  2002influential reference
• Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

  2002influential reference
• The vicious cycle of bone metastases.

  2002influential reference
• Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

  2002influential reference
• Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

  2001influential reference
• Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

  2001influential reference
• Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

  2001influential reference
• Synthesis of N-quaternary ammonium [3H] and [99mTc]polyazamacrocycles, potential radiotracers for cartilage imaging

  2000cited by this paper
• Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.

  2000influential reference
• Temperature-sensitive Differential Affinity of TRAIL for Its Receptors

  2000influential reference
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998influential reference
• Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

  1998influential reference
• Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor*

  1998influential reference
• Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*

  1998influential reference

• Novel Function of Osteoprotegerin in the Modulation of Glucose Metabolism in the Liver via mTORC1.

  2025cites this paper
• Plasma TNFRSF11B as a New Predictive Inflammatory Marker of Sepsis–ARDS with Endothelial Dysfunction

  2023cites this paper
• Advances in Osteosarcoma

  2023cites this paper
• Angiotensin II Induces Aortic Rupture and Dissection in Osteoprotegerin‐Deficient Mice

  2022cites this paper
• Characterization of large yellow croaker (Larimichthys crocea) osteoprotegerin and its role in the innate immune response against to Vibrio alginolyticus.

  2021cites this paper
• Role of microRNAs in the crosstalk between osteosarcoma cells and the tumour microenvironment

  2020cites this paper
• Molecular mechanisms and clinical management of cancer bone metastasis

  2020cites this paper
• Identification of co-expression modules and pathways correlated with osteosarcoma and its metastasis

  2019cites this paper
• Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond

  2019cites this paper
• Supramolecular Gene Transfection Agents

  2017cites this paper
• Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization.

  2017cites this paper
• Heparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis*

  2016cites this paper
• RANK–RANKL signalling in cancer

  2016cites this paper
• Anti-Metastatic Properties of a Marine Bacterial Exopolysaccharide-Based Derivative Designed to Mimic Glycosaminoglycans

  2016cites this paper
• Knockdown of ST6Gal-I inhibits the growth and invasion of osteosarcoma MG-63 cells.

  2015cites this paper
• Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma

  2015cites this paper
• Sulfated Glycosaminoglycans Support Osteoblast Functions and Concurrently Suppress Osteoclasts

  2014cites this paper
• Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.

  2014cites this paper
• Osteoprotegerin and kidney disease

  2014influential citation
• Novel RANK Antagonists for the Treatment of Bone‐Resorptive Disease: Theoretical Predictions and Experimental Validation

  2014cites this paper
• The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-κB ligand/osteoprotegerin complex formation.

  2013cites this paper
• Sulfated glycosaminoglycans from crown-of-thorns Acanthaster planci – extraction and quantification analysis

  2013influential citation
• Glycosaminoglycan mimetic peptide nanofibers promote mineralization by osteogenic cells.

  2013cites this paper
• Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL

  2013cites this paper
• Osteoprotegerin: multiple partners for multiple functions.

  2013influential citation
• Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis.

  2013cites this paper
• L’ostéoprotégérine, nouvel acteur dans l’angiogenèse : Rôle dans la formation de nouveaux vaisseaux et mécanisme d’action

  2013cites this paper
• Mechanistic study of the proangiogenic effect of osteoprotegerin

  2013cites this paper
• Proteoglycans and osteolysis.

  2012cites this paper
• In vivo scintigraphic imaging of proteoglycans.

  2012cites this paper
• Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences

  2012cites this paper
• Binding efficiency of protein-protein complexes.

  2012cites this paper
• BIOMIMETIC SELF-ASSEMBLED PEPTIDE NANOFIBERS

  2012cites this paper
• Relevance of the POS-1 Orthotopic Model as an “Imaging Model” for In Vivo and Simultaneous Monitoring of Tumor Proliferation and Bone Remodeling in Osteosarcoma

  2012cites this paper
• Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony‐forming cells properties

  2011cites this paper
• Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption.

  2011cites this paper
• Can heparins stimulate bone cancer stem cells and interfere with tumorigenesis?

  2011cites this paper
• Regenerative potential of glycosaminoglycans for skin and bone

  2011cites this paper
• Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation

  2011cites this paper
• Docking glycosaminoglycans to proteins: analysis of solvent inclusion

  2011cites this paper
• Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions.

  2011cites this paper
• Effects of a sulfated exopolysaccharide produced by Altermonas infernus on bone biology.

  2011cites this paper
• Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.

  2010cites this paper
• Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

  2010cites this paper
• Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence

  2010cites this paper
• Phage Display–Derived Peptides for Osteosarcoma Imaging

  2010cites this paper
• Proteoglycans on bone tumor development.

  2010cites this paper
• Aspects of bone sugar biology : pectin nanocoatings of hard tissue implants

  2009influential citation
• Profiling of Chemonaive Osteosarcoma and Paired-Normal Cells Identifies EBF2 as a Mediator of Osteoprotegerin Inhibition to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

  2009cites this paper